Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 9:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 212 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Oral Bacterial Infection Clear all
Completed Phase 2 Interventional Results available

Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea

NCT02257918
View directory record Official record
Conditions
Gonorrhoea
Interventions
AZD0914, Ceftriaxone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
Birmingham, Alabama • Indianapolis, Indiana • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122

NCT04634513
View directory record Official record
Conditions
Shigella Infection, Enterotoxigenic Escherichia Coli Infection
Interventions
strain CVD 1208S-122, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers

NCT02214433
View directory record Official record
Conditions
Bacterial Infections
Interventions
Placebo IV Solution, Debio 1450 IV Solution, Placebo Tablet or Capsule, Debio 1450 Tablet, Debio 1450 Capsule, Debio 1450 Oral Solution, Pantoprazole
Drug
Lead sponsor
Debiopharm International SA
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2015 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Test the Effects of Itraconazole and Carbamazepine on OPC-167832 in Healthy Men and Women

NCT07542847
View directory record Official record
Conditions
Healthy Volunteers
Interventions
OPC-167832, Itraconazole, Carbamazepine
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 17, 2026, 9:49 PM EDT
Recruiting No phase listed Observational

Natural History of Trisomy 8-Associated Autoinflammatory Disease (TRIAD) and Related Disorders

NCT07683104
View directory record Official record
Conditions
Trisomy 8 Mosaicism, Trisomy 8 Associated Autoinflammatory Disease, Mucosal Ulcerations
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2056
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 17, 2026, 9:49 PM EDT
Terminated Phase 3 Interventional Results available

A Trial of CP101 for the Prevention of Recurrent CDI (PRISM4)

NCT05153499
View directory record Official record
Conditions
Recurrent C. Difficile Infection
Interventions
CP101, Placebo
Biological · Other
Lead sponsor
Finch Research and Development LLC.
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
61
States / cities
Phoenix, Arizona • Mission Hills, California • Oakland, California + 51 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Aging on Primary and Secondary Vaccine Responses

NCT03312699
View directory record Official record
Conditions
Influenza, Hepatitis A, Typhoid, Healthy Adults
Interventions
Fluzone® quadrivalent, Fluzone High Dose, Fluad, Vaqta, Typhim Vi, Vivotif
Biological
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Sep 17, 2026, 9:49 PM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

NCT05178862
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia
Interventions
SCY-078, Fluconazole, Echinocandin
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 1 Interventional

A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP

NCT00000998
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Trimetrexate glucuronate, Leucovorin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1989
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia

NCT02813694
View directory record Official record
Conditions
Community Acquired Pneumonia
Interventions
lefamulin, Moxifloxacin
Drug
Lead sponsor
Nabriva Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Beverly Hills, California • Fresno, California • Northridge, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV

NCT03937869
View directory record Official record
Conditions
Bacterial Vaginoses
Interventions
Secnidazole
Drug
Lead sponsor
Lupin Research Inc
Industry
Eligibility
12 Years to 17 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
9
States / cities
Long Beach, California • Hialeah, Florida • Miami Lakes, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 3 Interventional Results available

Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)

NCT02531438
View directory record Official record
Conditions
Bacterial Pneumonia, Community-Acquired Infections
Interventions
Omadacycline, Moxifloxacin
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
774 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Birmingham, Alabama • Mobile, Alabama • Laguna Hills, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2019 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of VT-1598

NCT04208321
View directory record Official record
Conditions
Coccidioidomycosis
Interventions
Placebo, VT-1598
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2024 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 3 Interventional Results available

The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo

NCT00997035
View directory record Official record
Conditions
Corneal Ulcer, Eye Infections, Fungal
Interventions
Voriconazole, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
16 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Itraconazole Oral Absorption

NCT04035187
View directory record Official record
Conditions
Fungal Infection
Interventions
fast itraconazole tablet, medium itraconazole tablet, slow itraconazole tablet, oral itraconazole solution
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Inactivated Shigella Whole Cell Vaccine in Adults

NCT01509846
View directory record Official record
Conditions
Shigellosis
Interventions
Vaccine: 2.6±0.8 x 10^8 vp/mL, 1 dose, Vaccine: 2.6±0.8 x 10^9 vp/mL, 3 doses, Vaccine: 2.6±0.8 x 10^10 vp/mL, 3 doses, Vaccine: 2.6±0.8 x 10^11 vp/mL, 3 doses, Placebo: 1-3 doses
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

NCT01663389
View directory record Official record
Conditions
Infections, Bacterial
Interventions
GSK1322322 1000 mg containing radioactive 14C-GSK1322322, GSK1322322 1200 mg containing radioactive 14C-GSK1322322
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 2 Interventional Results available

Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection

NCT00739934
View directory record Official record
Conditions
Candidiasis, Candidemia
Interventions
voriconazole (Vfend)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Tucson, Arizona • Orange, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2011 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Not applicable Interventional

Evaluation of Amphotericin B in the Treatment of Biopsy Proven Candida Esophagitis in Immunocompromised Patients

NCT00002041
View directory record Official record
Conditions
Candidiasis, Esophageal, HIV Infections
Interventions
Amphotericin B
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

NCT01610388
View directory record Official record
Conditions
Infections, Bacterial
Interventions
500mg IV GSK1322322/placebo, 1000mg oral GSK1322322/placebo, 1000mg IV GSK1322322/placebo, 1500mg oral GSK1322322/placebo dose, 1500mg IV GSK1322322/placebo, 2000mg IV GSK1322322J/placebo, 3000mg IV GSK1322322J/placebo, 1000mg IV GSK1322322J/placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 11, 2017 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

NCT03562156
View directory record Official record
Conditions
Recurrent Vulvovaginal Candidiasis
Interventions
Oteseconazole (VT-1161), Placebo
Drug
Lead sponsor
Mycovia Pharmaceuticals Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
25
States / cities
Birmingham, Alabama • San Diego, California • Lauderdale Lakes, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Moderate - Severe Interdigital Tinea Pedis

NCT01891305
View directory record Official record
Conditions
Tinea Pedis
Interventions
VT-1161, placebo
Drug
Lead sponsor
Viamet
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • Miami, Florida • Miramar, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Sep 17, 2026, 9:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis

NCT03987620
View directory record Official record
Conditions
Candida Vulvovaginitis
Interventions
Ibrexafungerp, Placebo
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
12 Years and older · Female only
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
21
States / cities
Mesa, Arizona • Lakewood, Colorado • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2021 · Synced Sep 17, 2026, 9:49 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Follow-up of Pregnant Women After a Mass Vaccination of Oral Cholera Vaccine (ShancholTM) in Nsanje Malawi

NCT02499172
View directory record Official record
Conditions
Miscarriage, Stillbirth, Cholera
Interventions
Shanchol
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
15 Years to 49 Years · Female only
Enrollment
2,758 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Sep 17, 2026, 9:49 PM EDT